innosferaНаука и инновацииScience and Innovations1818-98572412-9372Издательский дом «Белорусская наука»10.29235/1818-9857-2026-09-79-83innosfera-1113Research ArticleДИССЕРТАЦИОННЫЕ ИССЛЕДОВАНИЯDISSERTATION RESEARCHТехнология CAR-NK: новые шаги в лечении онкологических заболеванийCAR-NK technology: new steps in cancer treatmentЛебедеваЮ.LebedevaYuliya

Юлия Лебедева, младший научный сотрудник лаборатории иммунологических исследований 

lebedevaula859@gmail.comВашкевичЕ.VashkevichEkaterina

 Екатерина Вашкевич, старший научный сотрудник  

 

immunology@oncology.byБелевцевМ.BelevtsevMikhail

Михаил Белевцев, заместитель директора по науке, кандидат биологических наук, доцент 

belevtsev_m@mail.ruРНПЦ детской онкологии, гематологии и иммунологии Belarus202613102026097983Copyright © Лебедева Ю., Вашкевич Е., Белевцев М., 20262026Лебедева Ю., Вашкевич Е., Белевцев М.Lebedeva Y., Vashkevich E., Belevtsev M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://innosfera.belnauka.by/jour/article/view/1113

На примере технологии CAR-NK рассмотрены актуальные достижения современной иммунотерапии и выделены ключевые преимущества применения медицинской генной инженерии в онкологии. 

Using genetically modified natural killer (NK) cells expressing a chimeric antigen receptor (CAR) as an example, recent advances in the field of cancer immunotherapy are reviewed. Taking into account the biological characteristics of NK cells, the main advantages and features of CAR-NK technology, an actively developing area of medical genetic engineering, are identified. Unlike CAR-T, CAR-NK cells demonstrate a reduced risk of adverse reactions, which enables the creation of «universal» allogeneic constructs. The innate ability of NK cells to recognize tumor cells independently of the MHC complex is enhanced through additional genetic modifications, including the insertion of genes encoding pro-inflammatory cytokines. Overcoming the immunosuppressive tumor microenvironment of solid malignancies remains a promising direction, as does increasing the resistance of NK cells to apoptosis. Current clinical trials confirm the safety and efficacy of CAR-NK cells in malignant neoplasms, which stimulates further developments in this field.

chimeric antigen receptorCAR-NKcytokinesimmunotherapygenetic engineeringReferencesEfficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis / H. Park [et al.] // Frontiers in Immunology. 2024. Vol. 15. P. 1454427.Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis / H. Park [et al.] // Frontiers in Immunology. 2024. Vol. 15. P. 1454427.N K - c e l l b a s e d c a n c e r i m m u n o t h e r a p y : from basic biology to clinical development / S. Liu [et al.] // Journal of Hematology & Oncology. 2021. Vol. 14, №7. P. 17.N K - c e l l b a s e d c a n c e r i m m u n o t h e r a p y : from basic biology to clinical development / S. Liu [et al.] // Journal of Hematology & Oncology. 2021. Vol. 14, №7. P. 17.Wu X. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy / X. Wu, S. Matosevic // Molecular therapy oncolytics. 2022. Vol. 27. P. 224–238.Wu X. Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy / X. Wu, S. Matosevic // Molecular therapy oncolytics. 2022. Vol. 27. P. 224–238.Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xeno gr af t mice / F. Liu [e t al.] // Nature communications. 2025. Vol.16, №1. P. 8809.Selective HLA knockdown and PD-L1 expression prevent allogeneic CAR-NK cell rejection and enhance safety and anti-tumor responses in xeno gr af t mice / F. Liu [e t al.] // Nature communications. 2025. Vol.16, №1. P. 8809.KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease / J. Dębska-Zielkowska [et al.] // Cells. 2021. Vol. 10, №7. P. 1777.KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease / J. Dębska-Zielkowska [et al.] // Cells. 2021. Vol. 10, №7. P. 1777.The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer / N. Li [et al.] // Nature communications. 2023. Vol. 14, №1. P. 1986.The IgG4 hinge with CD28 transmembrane domain improves VHH-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer / N. Li [et al.] // Nature communications. 2023. Vol. 14, №1. P. 1986.Herrera L. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells / L. Herrera // Scientific Reports. 2019. Vol. 9. P. 18729.Herrera L. Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells / L. Herrera // Scientific Reports. 2019. Vol. 9. P. 18729.2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity / M.H. dos Santos [et al.] // Frontiers in Immunology. 2025. Vol. 16 P. 1675877.2B4 co-stimulation and dasatinib modulation enhance anti-CD19 CAR-NK-92 cell cytotoxicity / M.H. dos Santos [et al.] // Frontiers in Immunology. 2025. Vol. 16 P. 1675877.DAP12- b a s e d ac t i v at i n g c hi m e r ic an t i g e n receptor for NK cell tumor immunotherapy / K. Töpfer [et al.] // The Journal of Immunology. 2015. Vol. 194, №7. P. 3201–3212.DAP12- b a s e d ac t i v at i n g c hi m e r ic an t i g e n receptor for NK cell tumor immunotherapy / K. Töpfer [et al.] // The Journal of Immunology. 2015. Vol. 194, №7. P. 3201–3212.Comparison of seven CD19 C AR designs in engineering NK cells for enhancing anti-tumour activity / Y. Wang [et al.] // Cell Proliferation. 2024. P. 13683.Comparison of seven CD19 C AR designs in engineering NK cells for enhancing anti-tumour activity / Y. Wang [et al.] // Cell Proliferation. 2024. P. 13683.CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis / S. Acharya [et al.] // Cancer Discovery. 2024. Vol. 14. №10. P. 1879–1900.CD28 Costimulation Augments CAR Signaling in NK Cells via the LCK/CD3ζ/ZAP70 Signaling Axis / S. Acharya [et al.] // Cancer Discovery. 2024. Vol. 14. №10. P. 1879–1900.Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectors / E. Järvelä [et al.] // (Preprint). 2026. P. 710988.Efficient NK cell transduction with VSV-G-pseudotyped lentiviral vectors / E. Järvelä [et al.] // (Preprint). 2026. P. 710988.Schmidt P. Engineering NK Cells for CAR TherapyRecent Advances in Gene Transfer Methodology / P. Schmidt, M.J. Raftery, G. Pecher // Frontiers in Immunology. 2021. Vol. 11. P. 611163.Schmidt P. Engineering NK Cells for CAR TherapyRecent Advances in Gene Transfer Methodology / P. Schmidt, M.J. Raftery, G. Pecher // Frontiers in Immunology. 2021. Vol. 11. P. 611163.Co lamar t ino Effi c ient an d Ro b u s t NK- Ce ll Transduction With Baboon Envelope Pseudotyped Lentivector / B. L. Aurelien [et al.] // Sec. Cancer Immunity and Immunotherapy. 2019. Vol. 10. P. 2873.Co lamar t ino Effi c ient an d Ro b u s t NK- Ce ll Transduction With Baboon Envelope Pseudotyped Lentivector / B. L. Aurelien [et al.] // Sec. Cancer Immunity and Immunotherapy. 2019. Vol. 10. P. 2873.Wang X. Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development / X. Wang, X.Y. Zhao // Frontiers in Immunology. 2021. Vol. 12. P. 610789.Wang X. Transcription Factors Associated With IL-15 Cytokine Signaling During NK Cell Development / X. Wang, X.Y. Zhao // Frontiers in Immunology. 2021. Vol. 12. P. 610789.Use of CAR-Transduced Natural Killer Cells in CD19- Positive Lymphoid Tumors / E. Liu [et al.] // The New England Journal of Medicine. 2020. Vol. 382, №6. P. 545–553.Use of CAR-Transduced Natural Killer Cells in CD19- Positive Lymphoid Tumors / E. Liu [et al.] // The New England Journal of Medicine. 2020. Vol. 382, №6. P. 545–553.Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities / I. Christodoulou [et al.] // Journal for ImmunoTherapy of Cancer. 2021. Vol. 9, №12. P. 3894.Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities / I. Christodoulou [et al.] // Journal for ImmunoTherapy of Cancer. 2021. Vol. 9, №12. P. 3894.Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells / X. Xu [et al.] // Frontiers in Immunology. 2025. Vol. 16. P. 1658580.Signaling intact membrane-bound IL-15 enables potent anti-tumor activity and safety of CAR-NK cells / X. Xu [et al.] // Frontiers in Immunology. 2025. Vol. 16. P. 1658580.

The authors declare that there are no conflicts of interest present.